Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop
Recent clinical practice guidelines for diabetes, obesity, cardiovascular disease (CVD) and chronic kidney disease (CKD) emphasise a holistic, person-centred approach to care. However, they do not include recommendations for the assessment of patient-reported outcomes (PROs), which would - dependent on the topic of guideline - be important for improving shared decision-making, patients' concordance with guideline recommendations, clinical outcomes and health-related quality of life (HRQoL). The Taskforce of the Guideline Workshop discussed PROs in diabetes, obesity, CVD and CKD as well as the relevance of their inclusion in clinical practice guidelines for the management of these conditions.
Authors
- Nebojša Lalić (ORCID: https://orcid.org/0000-0002-8082-6560)
- Frank C. Brosius (ORCID: https://orcid.org/0000-0002-4244-8335)
- Oliver Schnell (ORCID: https://orcid.org/0000-0003-4968-2367)
- Per Olav Vandvik (ORCID: https://orcid.org/0000-0001-8958-2710)
- René D. Rötzer (ORCID: https://orcid.org/0009-0001-6667-5188)
- Nikolaus Marx (ORCID: https://orcid.org/0000-0001-6141-634X)
- Helena W. Rodbard (ORCID: https://orcid.org/0000-0002-6187-8445)
- Prashant Nedungadi
- Wayne Huey‐Herng Sheu (ORCID: https://orcid.org/0000-0002-8805-8340)
- Christopher G. Parkin (ORCID: https://orcid.org/0000-0001-6838-5355)
- Christoph Wanner (ORCID: https://orcid.org/0000-0001-9507-5301)
- Monika Kellerer (ORCID: https://orcid.org/0000-0002-9834-5976)
- Katharine Barnard‐Kelly (ORCID: https://orcid.org/0000-0002-3888-3123)
- Lars Rydén (ORCID: https://orcid.org/0000-0002-5430-4697)
- Antonio Ceriello (ORCID: https://orcid.org/0000-0001-8122-3203)
- Sue Koob
- Tadej Battelino (ORCID: https://orcid.org/0000-0002-0273-4732)
- Mikhail Kosiborod (ORCID: https://orcid.org/0000-0002-3750-9789)
- Britta Tendal Jeppesen
- Francesco Giorgino (ORCID: https://orcid.org/0000-0001-7372-2678)
- Pınar Topsever (ORCID: https://orcid.org/0000-0001-7119-8569)
- Francesco Cosentino (ORCID: https://orcid.org/0000-0002-6967-5685)
- Eberhard Standl (ORCID: https://orcid.org/0000-0002-8667-633X)
- Jennifer Green (ORCID: https://orcid.org/0000-0002-3541-4989)
- Linong Ji (ORCID: https://orcid.org/0000-0001-5257-7512)
- James R. Gavin (ORCID: https://orcid.org/0000-0003-4901-8781)
Institutions
- American Heart Association (US)
- Karolinska University Hospital (SE)
- University of Arizona (US)
- Emory University (US)
- University of Ljubljana (SI)
- National Health Research Institutes (TW)
- University of Oslo (NO)
- Peking University (CN)
- Ljubljana University Medical Centre (SI)
- Southern Health NHS Foundation Trust (GB)
- Karolinska Institutet (SE)
- Helmholtz Zentrum München (DE)
- University of Belgrade (RS)
- Clinical Research Institute (US)
- MultiMedica (IT)
- Marienhospital Stuttgart (DE)
- Universitätsklinikum Aachen (DE)
- Peking University People's Hospital (CN)
- Duke Medical Center (US)
- Universitätsklinikum Würzburg (DE)
- Saint Luke's Hospital (US)
- Kent Hastanesi (TR)
- Acıbadem Adana Hospital (TR)
- University of Bari Aldo Moro (IT)
- University of Missouri–Kansas City (US)
- RWTH Aachen University (DE)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1186/s12933-024-02550-2
- Citations
- 13
- Primary Topic
- Clinical practice guidelines implementation
- Type
- article
- Field-Weighted Citation Impact
- 24.42
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Bayer
- Sanofi
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Cytokinetics
- Dexcom
- Novo Nordisk
- Vifor Pharma
- Roche Diabetes Care
- Esperion Therapeutics
- Abbott Diabetes Care
- Janssen Pharmaceuticals